Floatz logo

Veliparib

Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation

Small moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
D
Vinorelbine
D

Same molecule, other indications

Veliparib is also rated in:

non-small cell lung carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Stage IV Pancreatic CancerDormant
BB
Indicative ·
71 / 100
View asset →
small cell lung carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →